{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:09:38Z","timestamp":1744355378172,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA050985"],"award-info":[{"award-number":["R25DA050985"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study examined associations between receipt of hepatitis C (HCV) treatment and retention in office-based opioid treatment (OBOT) care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cohort study of HCV-infected patients who initiated OBOT treatment between December 2015 and March 2021 to characterize HCV treatment and assess associations with OBOT retention. HCV treatment was characterized as no treatment, early treatment (&lt;\u2009100\u00a0days since OBOT initiation) or late treatment (\u2265\u2009100\u00a0days). We evaluated associations between HCV treatment and cumulative days in OBOT. A secondary analysis using Cox Proportional Hazards regression was done to determine the rate of discharge over time when comparing those who did versus did not receive HCV treatment as a time-varying covariate. We also analyzed a subset of patients retained at least 100\u00a0days in OBOT care and evaluated whether HCV treatment during that period was associated with OBOT retention beyond 100\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 191 HCV-infected OBOT patients, 30% initiated HCV treatment, of whom 31% received early treatment and 69% received late treatment. Median cumulative duration in OBOT was greater among those who received HCV treatment (any: 398\u00a0days, early: 284\u00a0days and late: 430\u00a0days) when compared to those who did not receive treatment (90\u00a0days). Compared to no HCV treatment, there were 83% (95% CI: 33\u2013152%, P\u2009&lt;\u20090.001), 95% (95% CI: 28%-197%, p\u2009=\u20090.002 and 77% (95% CI: 25\u2013153%, p\u2009=\u20090.002) more cumulative days in OBOT for any, early and late HCV treatment, respectively. HCV treatment was associated with a lower relative hazard for discharge\/drop-out, although results did not meet statistical significance (aHR\u2009=\u20090.59;95% CI: 0.34\u20131.00; p\u2009=\u20090.052). Among the subset of 84 patients retained in OBOT at least 100\u00a0days, 18 received HCV treatment during that period. Compared to those who did not receive treatment within the first 100\u00a0days, those who received treatment had 57% (95% CI: -3%-152%, p\u2009=\u20090.065) more subsequent days in OBOT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A minority of HCV-infected patients received HCV treatment after initiating OBOT treatment, but those who did had better retention. Further efforts are needed to facilitate rapid HCV treatment and evaluate whether early HCV treatment improves OBOT engagement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-023-00389-8","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T07:02:04Z","timestamp":1684998124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Mary L.","family":"Geist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea C.","family":"Radick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra L.","family":"Blalock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addy","family":"Adwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsabeth","family":"Tamru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy C.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1980-6579","authenticated-orcid":false,"given":"Jocelyn R.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"389_CR1","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis surveillance report 2018\u2014hepatitis C. Updated August 28, 2020. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2018surveillance\/HepC.htm. Accessed 4 Feb 2022."},{"issue":"Suppl 2","key":"389_CR2","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1093\/cid\/cit296","volume":"57","author":"NK Martin","year":"2013","unstructured":"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(Suppl 2):S39-45. https:\/\/doi.org\/10.1093\/cid\/cit296.","journal-title":"Clin Infect Dis"},{"key":"389_CR3","unstructured":"Committee on a National Strategy for the Elimination of Hepatitis B, Board on Population H, Public Health P, et al. In: Buckley GJ, Strom BL, eds. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. National Academies Press (US). Copyright 2016 by the National Academy of Sciences. All rights reserved; 2016."},{"issue":"2","key":"389_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41591-019-0706-x","volume":"26","author":"GJ Dore","year":"2020","unstructured":"Dore GJ, Martinello M, Alavi M, Grebely J. Global elimination of hepatitis C virus by 2030: why not? Nat Med. 2020;26(2):157\u201360. https:\/\/doi.org\/10.1038\/s41591-019-0706-x.","journal-title":"Nat Med"},{"issue":"10","key":"389_CR5","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1111\/add.15459","volume":"116","author":"NE Palmateer","year":"2021","unstructured":"Palmateer NE, McAuley A, Dillon JF, et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. Addiction. 2021;116(10):2893\u2013907. https:\/\/doi.org\/10.1111\/add.15459.","journal-title":"Addiction"},{"key":"389_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","volume":"47","author":"BL Norton","year":"2017","unstructured":"Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196\u2013201. https:\/\/doi.org\/10.1016\/j.drugpo.2017.07.021.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"389_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.7326\/M16-0816","volume":"165","author":"GJ Dore","year":"2016","unstructured":"Dore GJ, Altice F, Litwin AH, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625\u201334. https:\/\/doi.org\/10.7326\/M16-0816.","journal-title":"Ann Intern Med"},{"issue":"3","key":"389_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(17)30404-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"389_CR9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","volume":"3","author":"B Hajarizadeh","year":"2018","unstructured":"Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754\u201367. https:\/\/doi.org\/10.1016\/S2468-1253(18)30304-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"389_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jhep.2018.09.030","volume":"70","author":"J Iversen","year":"2019","unstructured":"Iversen J, Dore GJ, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J Hepatol. 2019;70(1):33\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.030.","journal-title":"J Hepatol"},{"issue":"4","key":"389_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/cid\/ciab546","volume":"74","author":"SR Bartlett","year":"2022","unstructured":"Bartlett SR, Wong S, Yu A, et al. The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from the direct-acting antiviral (DAA) era: a population-based study. Clin Infect Dis. 2022;74(4):575\u201383. https:\/\/doi.org\/10.1093\/cid\/ciab546.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"389_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","volume":"72","author":"B Hajarizadeh","year":"2020","unstructured":"Hajarizadeh B, Cunningham EB, Valerio H, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. J Hepatol. 2020;72(4):643\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.012.","journal-title":"J Hepatol"},{"key":"389_CR13","unstructured":"NIH Consensus Development Program. Management of hepatitis C. National Institutes of Health; 1997; p. 1\u201341."},{"issue":"6","key":"389_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2105\/AJPH.2017.303748","volume":"107","author":"JM Liao","year":"2017","unstructured":"Liao JM, Fischer MA. Restrictions of hepatitis C treatment for substance-using medicaid patients: cost versus ethics. Am J Public Health. 2017;107(6):893\u20139. https:\/\/doi.org\/10.2105\/AJPH.2017.303748.","journal-title":"Am J Public Health"},{"key":"389_CR15","unstructured":"Centers for Disease Control and Prevention. Hepatitis C information. 2022. https:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm#d7;%20AASLD\/IDSA%20guideline:%20hcvguidelines.org. Accessed 4 Feb 2022."},{"key":"389_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2019.07.016","volume":"72","author":"J Grebely","year":"2019","unstructured":"Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C, International Network on Hepatitis in Substance U. Elimination of hepatitis C virus infection among people who use drugs: ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy. 2019;72:1\u201310. https:\/\/doi.org\/10.1016\/j.drugpo.2019.07.016.","journal-title":"Int J Drug Policy"},{"key":"389_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.drugpo.2019.06.002","volume":"72","author":"J Bryant","year":"2019","unstructured":"Bryant J, Rance J, Hull P, Mao L, Treloar C. Making sense of \u201cside effects\u201d: counterpublic health in the era of direct-acting antivirals. Int J Drug Policy. 2019;72:77\u201383. https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.002.","journal-title":"Int J Drug Policy"},{"key":"389_CR18","unstructured":"Health Care Authority. Eliminating Hepatitis C in Washington State. Clinical quality and care transformation. 2019. https:\/\/www.hca.wa.gov\/assets\/program\/HCA-HCV-elimination-breif.pdf. Accessed 13 Jan 2023."},{"issue":"9","key":"389_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(9):979\u201393. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976.","journal-title":"JAMA Psychiat"},{"key":"389_CR20","doi-asserted-by":"publisher","first-page":"108116","DOI":"10.1016\/j.drugalcdep.2020.108116","volume":"213","author":"B Severe","year":"2020","unstructured":"Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug Alcohol Depend. 2020;213:108116. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108116.","journal-title":"Drug Alcohol Depend"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.drugalcdep.2015.06.007","volume":"153","author":"AW Batchelder","year":"2015","unstructured":"Batchelder AW, Peyser D, Nahvi S, Arnsten JH, Litwin AH. \u201cHepatitis C treatment turned me around:\u201d Psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend. 2015;153:66\u201371. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.06.007.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"389_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12879-018-3057-1","volume":"18","author":"S Goutzamanis","year":"2018","unstructured":"Goutzamanis S, Doyle JS, Thompson A, et al. Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study. BMC Infect Dis. 2018;18(1):151. https:\/\/doi.org\/10.1186\/s12879-018-3057-1.","journal-title":"BMC Infect Dis"},{"key":"389_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","volume":"109","author":"JI Tsui","year":"2020","unstructured":"Tsui JI, Mayfield J, Speaker EC, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2020;109:80\u20135. https:\/\/doi.org\/10.1016\/j.jsat.2019.10.005.","journal-title":"J Subst Abuse Treat"},{"key":"389_CR24","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550.","journal-title":"BMJ"},{"key":"389_CR25","unstructured":"Ahmad F, Rossen L, Sutton P, National Center for Health Statistics. Provisional drug overdose death counts. National Center for Health Statistics,. Updated May 12, 2021. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed 14 Feb 2022."},{"key":"389_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jsat.2016.01.009","volume":"66","author":"KJ Carey","year":"2016","unstructured":"Carey KJ, Huang W, Linas BP, Tsui JI. Hepatitis C virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders. J Subst Abuse Treat. 2016;66:54\u20139. https:\/\/doi.org\/10.1016\/j.jsat.2016.01.009.","journal-title":"J Subst Abuse Treat"},{"key":"389_CR27","doi-asserted-by":"publisher","first-page":"108525","DOI":"10.1016\/j.drugalcdep.2021.108525","volume":"220","author":"MA Corcorran","year":"2021","unstructured":"Corcorran MA, Tsui JI, Scott JD, Dombrowski JC, Glick SN. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle. Washington Drug Alcohol Depend. 2021;220:108525. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108525.","journal-title":"Washington. Drug Alcohol Depend."},{"issue":"32","key":"389_CR28","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.3748\/wjg.v26.i32.4878","volume":"26","author":"I Houri","year":"2020","unstructured":"Houri I, Horowitz N, Katchman H, et al. Emergency department targeted screening for hepatitis C does not improve linkage to care. World J Gastroenterol. 2020;26(32):4878\u201388. https:\/\/doi.org\/10.3748\/wjg.v26.i32.4878.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"389_CR29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.ajem.2019.11.034","volume":"38","author":"JA Blackwell","year":"2020","unstructured":"Blackwell JA, Rodgers JB, Franco RA, et al. Predictors of linkage to care for a nontargeted emergency department hepatitis C screening program. Am J Emerg Med. 2020;38(7):1396\u2013401. https:\/\/doi.org\/10.1016\/j.ajem.2019.11.034.","journal-title":"Am J Emerg Med"},{"key":"389_CR30","doi-asserted-by":"publisher","first-page":"711941","DOI":"10.3389\/fdgth.2021.711941","volume":"3","author":"A Mascio","year":"2021","unstructured":"Mascio A, Stewart R, Botelle R, et al. Cognitive impairments in schizophrenia: a study in a large clinical sample using natural language processing. Front Digit Health. 2021;3:711941. https:\/\/doi.org\/10.3389\/fdgth.2021.711941.","journal-title":"Front Digit Health."},{"issue":"3","key":"389_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1377\/hlthaff.25.3.659","volume":"25","author":"M Horvitz-Lennon","year":"2006","unstructured":"Horvitz-Lennon M, Kilbourne AM, Pincus HA. From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Aff (Millwood). 2006;25(3):659\u201369. https:\/\/doi.org\/10.1377\/hlthaff.25.3.659.","journal-title":"Health Aff (Millwood)."},{"issue":"4","key":"389_CR32","doi-asserted-by":"publisher","first-page":"ofz100","DOI":"10.1093\/ofid\/ofz100","volume":"6","author":"HN Kim","year":"2019","unstructured":"Kim HN, Nance RM, Williams-Nguyen JS, et al. Effectiveness of direct-acting antiviral therapy in patients with human immunodeficiency virus-hepatitis C virus coinfection in routine clinical care: a multicenter study. Open Forum Infect Dis. 2019;6(4):ofz100. https:\/\/doi.org\/10.1093\/ofid\/ofz100.","journal-title":"Open Forum Infect Dis"},{"key":"389_CR33","unstructured":"Center for Health Law and Policy Innovation & National Viral Hepatitis Roundtable. Hepatitis C: state of medicaid access, National Summary Report. 2022. https:\/\/stateofhepc.org\/wp-content\/uploads\/2022\/06\/State-of-Hep-C-Report_2022-1.pdf."},{"key":"389_CR34","unstructured":"Washington State Health Care Authority. Eliminating hepatitis C. 2022. https:\/\/www.hca.wa.gov\/about-hca\/clinical-collaboration-and-initiatives\/eliminating-hepatitis-c#strategy. Accessed 31 Jul 2022."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00389-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T07:12:06Z","timestamp":1684998726000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00389-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00389-8","relation":{},"ISSN":["1940-0640"],"issn-type":[{"type":"electronic","value":"1940-0640"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Washington Institutional Review Board waived review after determining that this study did not constitute human subjects research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}